Heart failure & cardiomyopathiesRandomised controlled trial
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
- Randomised controlled trial
- international
- double-blind
- double-dummy
Authors' conclusion
Among patients with symptomatic obstructive HCM, aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics and decreasing symptoms.
Study context
- Population
- Adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM)
- Participants
- 88 vs 87
- Comparison
- Aficamten monotherapy vs metoprolol monotherapy
- Aficamtenn = 88
- Metoprololn = 87reference
- Primary endpoint
- Change in peak oxygen uptake
- Follow-up
- Week 24
Primary result
As reported in the abstract
Least-squares mean between-group difference
2.3 ml per kilogram per minute
95% CI 1.5–3.1
P < 0.001
By group
Aficamten
1.1
95% CI 0.5–1.7 · ml per kilogram of body weight per minute
Metoprolol
−1.2
95% CI −1.7–-0.8 · ml per kilogram per minute
Secondary outcomes
New York Heart Association (NYHA) class, Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), LV outflow tract gradient, NT-proBNP, left atrial volume index · week 24
- Significantly greater improvements with aficamten than with metoprolol
LV mass index · week 24
- No significant difference
Safety
Adverse events
- Appeared similar in the two treatment groups
Original publication
Summarised from the published abstract; every number is checked against it